The Food and Drug Administration yesterday issued final guidance for health care providers and researchers using investigational COVID-19 convalescent plasma, defined as convalescent plasma that does not meet all conditions of the agency’s emergency use authorization or which is used under an investigational new drug application during the public health emergency.

The updated guidance extends enforcement discretion through February 2021 to allow continued access to convalescent plasma for hospitalized COVID-19 patients while blood establishments develop operating procedures to manufacture the plasma consistent with the EUA.

The guidance also advises against collecting convalescent plasma from individuals who have received an investigational COVID-19 vaccine because the quality of the immune response from such vaccines is uncertain.

Related News Articles

Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…